Advanced Precision Medicine, Inc. engages Global Specimen Solutions, Inc. to identify molecular diagnostics for commercial launch in U.S. CLIA labs

Advanced Precision Medicine, Inc. (APM), a commercialization catalyst for molecular diagnostics, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc. (GSS), to qualify innovative molecular diagnostics for inclusion in the Syner-G portfolio of molecular diagnostics. APM’s Syner-G portfolio of molecular diagnostics includes applications in oncology, autoimmunity, wellness, and pain management.

Read Advanced Precision Medicine, Inc.’s Press Release Here